Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright
CLDX has been the topic of several other reports. ValuEngine downgraded Celldex Therapeutics from a sell rating to a strong sell rating in a research report on Friday, September 1st. Zacks Investment Research downgraded Celldex Therapeutics from a buy rating to a sell rating in a research report on Monday, July 17th. Cantor Fitzgerald reiterated a buy rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, BidaskClub downgraded Celldex Therapeutics from a sell rating to a strong sell rating in a research report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $6.31.
Celldex Therapeutics (NASDAQ:CLDX) opened at $2.73 on Tuesday. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $5.02.
Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm had revenue of $3.90 million for the quarter, compared to the consensus estimate of $1.30 million. During the same period in the prior year, the business posted ($0.29) earnings per share. The firm’s revenue for the quarter was up 77.3% compared to the same quarter last year. research analysts predict that Celldex Therapeutics will post -0.99 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/celldex-therapeutics-cldx-buy-rating-reiterated-at-hc-wainwright/1694804.html.
Institutional investors have recently added to or reduced their stakes in the company. BB&T Securities LLC purchased a new position in shares of Celldex Therapeutics in the 2nd quarter worth about $117,000. Voya Investment Management LLC raised its holdings in shares of Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 7,499 shares during the period. Overbrook Management Corp purchased a new position in shares of Celldex Therapeutics in the 2nd quarter worth about $139,000. Pacad Investment Ltd. purchased a new position in shares of Celldex Therapeutics in the 2nd quarter worth about $150,000. Finally, BlueCrest Capital Management Ltd purchased a new position in shares of Celldex Therapeutics in the 2nd quarter worth about $158,000. Institutional investors own 55.98% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.